Latest news with #PiotrSwat
Forbes
15-05-2025
- Business
- Forbes
Buy Or Fear Wheaton Precious Metals Stock?
POLAND - 2024/12/17: In this photo illustration, the Wheaton Precious Metals company logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images) Wheaton Precious Metals (NYSE:WPM) stock appears appealing but unpredictable – making it a difficult choice to acquire at its present price of approximately $76. We believe there is little reason for worry regarding WPM stock, which makes it appealing yet highly susceptible to negative events due to its exceedingly high valuation. We reach our assessment by analyzing the current valuation of WPM stock compared to its operational performance over recent years, as well as its current and historical financial status. Our evaluation of Wheaton Precious Metals based on key parameters of Growth, Profitability, Financial Stability, and Downturn Resilience indicates that the company has a very robust operational performance and financial health, as explained below. Nevertheless, if you are looking for upside with less volatility than individual stocks, the Trefis High-Quality portfolio provides an alternative – having surpassed the S&P 500 and delivered returns exceeding 91% since its launch. Based on what you pay per dollar of sales or profit, WPM stock seems very costly in relation to the wider market. • Wheaton Precious Metals holds a price-to-sales (P/S) ratio of 30.5 compared to a figure of 2.8 for the S&P 500 • Moreover, the company's price-to-free cash flow (P/FCF) ratio stands at 39.1 versus 17.6 for the S&P 500 • Additionally, it has a price-to-earnings (P/E) ratio of 56.0 compared to the benchmark's 24.5 Wheaton Precious Metals' Revenues have experienced notable growth in recent years. • Wheaton Precious Metals has witnessed its top line grow at an average rate of 2.0% over the last 3 years (compared to an increase of 6.2% for the S&P 500) • Its revenues have increased by 29.7% from $1.0 Bil to $1.3 Bil in the last 12 months (in contrast to a growth of 5.3% for the S&P 500) • Additionally, its quarterly revenues rose by 38.1% to $381 Mil in the most recent quarter from $313 Mil a year prior (versus a 4.9% improvement for the S&P 500) Wheaton Precious Metals' profit margins are significantly higher than most firms within the Trefis coverage universe. • Wheaton Precious Metals' Operating Income over the last four quarters reached $669 Mil, which reflects a remarkably high Operating Margin of 55.0% (compared to 13.1% for the S&P 500) • Wheaton Precious Metals' Operating Cash Flow (OCF) during this period was $950 Mil, indicating a notably high OCF Margin of 78.1% (compared to 15.7% for the S&P 500) • For the last four-quarter timeframe, Wheaton Precious Metals' Net Income was $609 Mil – suggesting a very high Net Income Margin of 50.1% (compared to 11.3% for the S&P 500) Wheaton Precious Metals' balance sheet appears solid. • Wheaton Precious Metals' Debt stood at $5.7 Mil at the end of the most recent quarter, while its market capitalization is $36 Bil (as of 5/13/2025). This indicates a very strong Debt-to-Equity Ratio of 0.0% (compared to 21.5% for the S&P 500). [Note: A low Debt-to-Equity Ratio is preferable] • Cash (including cash equivalents) accounts for $818 Mil of the $7.4 Bil in Total Assets for Wheaton Precious Metals. This results in a moderate Cash-to-Assets Ratio of 9.4% (compared to 15.0% for the S&P 500) WPM stock has proven to be more resilient than the benchmark S&P 500 index during certain recent downturns. While investors hope for a gentle landing by the U.S. economy, how severe could things become if another recession strikes? Our dashboard How Low Can Stocks Go During A Market Crash illustrates how key stocks performed during and following the last six market crashes. • WPM stock declined 43.8% from a high of $51.71 on 20 April 2022 to $29.08 on 26 September 2022, compared to a peak-to-trough drop of 25.4% for the S&P 500 • The stock completely rebounded to its pre-Crisis peak by 13 April 2023 • Since then, the stock has risen to a high of $85.77 on 11 May 2025 and currently trades around $76 • WPM stock fell 28.7% from a peak of $33.30 on 24 February 2020 to $23.74 on 19 March 2020, compared to a peak-to-trough decline of 33.9% for the S&P 500 • The stock fully recovered to its pre-Crisis peak by 13 April 2020 • WPM stock decreased 86.7% from a peak of $19.50 on 14 March 2008 to $2.59 on 20 November 2008, in contrast to a peak-to-trough drop of 56.8% for the S&P 500 • The stock successfully returned to its pre-Crisis peak by 30 April 2010 In conclusion, Wheaton Precious Metals' performance across the parameters outlined above is as follows: • Growth: Very Strong • Profitability: Extremely Strong • Financial Stability: Very Strong • Downturn Resilience: Strong • Overall: Very Strong Therefore, despite its exceedingly high valuation, the stock seems appealing but unpredictable, which reinforces our conclusion that WPM is a difficult stock to acquire. Not entirely content with the volatile nature of WPM stock? The Trefis High Quality (HQ) Portfolio, comprising 30 stocks, has a history of consistently outperforming the S&P 500 over the past four years. What accounts for this? In aggregate, HQ Portfolio stocks have yielded superior returns with reduced risk compared to the benchmark index; it has proven to be less of a roller-coaster ride, as demonstrated by HQ Portfolio performance metrics.
Forbes
05-05-2025
- Business
- Forbes
Time To Buy HHH Stock?
POLAND - 2025/04/26: In this photo illustration, the Howard Hughes Holdings company logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images) Recent reports have put Howard Hughes Holdings (NYSE:HHH) stock in the spotlight, revealing that Bill Ackman's Pershing Square Capital Management has secured a $900 million deal to increase its control over the company. This acquisition, priced at a substantial 48% premium over the Friday, May 2nd closing price of approximately $68, elevates Pershing Square's total stake to 46.9%. Given this significant development, a key question arises: Is HHH stock a buy at around $70? We think so. While acknowledging near-term headwinds such as elevated interest rates, macroeconomic uncertainty, and ongoing trade tensions, our conclusion is based on a comparative assessment of HHH stock's current valuation against its recent operating performance and its present and historical financial health. Our evaluation of Howard Hughes across crucial metrics—Growth, Profitability, Financial Stability, and Downturn Resilience—indicates a robust operating performance and a solid financial condition, the details of which are provided below. However, for investors who seek lower volatility than individual stocks, the Trefis High-Quality portfolio presents an alternative - having outperformed the S&P 500 and generated returns exceeding 91% since its inception. Going by what you pay per dollar of sales or profit, HHH stock looks slightly cheap compared to the broader market. Howard Hughes' Revenues have grown considerably over recent years. Howard Hughes' profit margins are around the median level for companies in the Trefis coverage universe. Howard Hughes' balance sheet looks weak. In summary, Howard Hughes' performance across the parameters detailed above are as follows: In summary, HHH stock has demonstrated strong performance across the aforementioned metrics, and its current valuation appears attractive. Therefore, we believe the stock presents a good buying opportunity at its current levels. Supporting this view, the average analyst price target of $90 suggests a potential upside of approximately 30% from the current price. While HHH stock looks promising, investing in a single stock can be risky. On the other hand, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.
Forbes
05-05-2025
- Business
- Forbes
JCI Q2 Earnings: How Will The Stock React?
POLAND - 2024/12/04: In this photo illustration, the Johnson Controls company logo is seen displayed ... More on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images) Johnson Controls International (NYSE:JCI) is scheduled to announce its earnings on Wednesday, May 7, 2025. In the past five years, JCI has experienced a positive one-day return after earnings releases in 56% of cases. When returns were positive, the median return was 2.2%, with a peak one-day positive return of 11.3%. For traders focused on specific events, comprehending these historical trends may provide a competitive advantage, although the actual market response will primarily rely on how the results stack up against consensus predictions and market expectations. There are two main methods to utilize this historical information: At present, consensus estimates indicate that JCI's earnings per share will be $0.79 on revenue of $5.63 billion. This is in comparison to the previous year's results of $0.78 earnings per share and $6.7 billion in revenue. From a fundamental point of view, JCI currently has a market capitalization of $59 billion. Its revenue over the last twelve months amounted to $22 billion, and the company showed operational profitability with $2.5 billion in operating profits and a net income of $1.8 billion. That said, if you're looking for upside with lower volatility than individual stocks, the Trefis High-Quality portfolio offers an alternative — having outperformed the S&P 500 and achieved returns exceeding 91% since its inception. See earnings reaction history of all stocks Here are some insights into one-day (1D) post-earnings returns: Further data for the observed 5-Day (5D) and 21-Day (21D) returns post-earnings is summarized alongside the statistics in the following table. JCI 1D, 5D, and 21D Post Earnings Return A relatively less risky strategy (though not effective if the correlation is weak) is to analyze the correlation between short-term and medium-term returns post-earnings, identify a pair with the highest correlation, and execute the appropriate trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can position themselves "long" for the following 5 days if the 1D post-earnings return is positive. Below is some correlation data based on 5-year and 3-year (more recent) history. Note that the correlation 1D_5D refers to the relationship between 1D post-earnings returns and subsequent 5D returns. JCI Correlation Between 1D, 5D, and 21D Historical Returns At times, the performance of peers can impact the post-earnings stock response. In fact, the pricing might start before the earnings are disclosed. Below is some historical information regarding the recent post-earnings performance of Johnson Controls International stock compared to the stock performance of peers that reported earnings just prior to Johnson Controls International. For accurate comparison, peer stock returns also denote post-earnings one-day (1D) returns. JCI Correlation With Peer Earnings Discover more about Trefis RV strategy that has outperformed all-cap stocks benchmarks (comprising all 3, the S&P 500, S&P mid-cap, and Russell 2000), delivering excellent returns for investors. Additionally, if you seek upside with a more stable experience than an individual stock such as Johnson Controls International, consider the High Quality portfolio, which has surpassed the S&P and achieved >91% returns since its inception.
Forbes
05-05-2025
- Business
- Forbes
How Will Wynn Stock React To Its Upcoming Q1 Earnings?
POLAND - 2025/02/07: In this photo illustration, the Wynn Resorts company logo is seen displayed on ... More a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images) Wynn stock (NASDAQ: WYNN) is set to announce its fiscal first-quarter earnings on Tuesday, May 6, 2025, with analysts anticipating earnings of $1.24 per share from $1.74 billion in revenue. This would indicate a 5% year-over-year decrease in earnings and a 6% reduction in sales compared to last year's figures of $1.30 per share and $1.86 billion in revenue. Historically, Wynn's stock has demonstrated a pattern of underperformance after earnings announcements, having declined 60% of the time, with a median one-day decrease of 2.0% and a maximum observed drop of 9%. In spite of short-term difficulties like macroeconomic pressures and uncertainties related to tariffs, WYNN is dedicated to long-term growth by focusing on premium customer segments and increasing its market share. The company is driving organic growth, bolstered by optimized pricing strategies and prudent cost management. Currently, WYNN has a market capitalization of $8.5 billion. Over the last twelve months, it recorded $7.1 billion in revenue, with $1.1 billion in operating profit and $501 million in net income. For traders focused on events, historical performance patterns and the disparity between actual results and analyst forecasts may offer valuable insights in anticipation of the upcoming earnings report. That said, if you are looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio presents an alternative, having outperformed the S&P 500 and achieving returns greater than 91% since its inception. See the earnings reaction history of all stocks. Some insights into one-day (1D) post-earnings returns: Additional information on observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized, alongside the statistics in the table below. WYNN 1D, 5D, and 21D Post Earnings Return A comparatively less risky strategy (although not beneficial if the correlation is low) is to examine the correlation between short-term and medium-term returns following earnings, identify a pair that exhibits the highest correlation, and implement the appropriate trade. For instance, if the correlation between 1D and 5D is the strongest, a trader can opt for a 'long' position for the next 5 days if the 1D post-earnings return is positive. Below is some correlation data based on both 5-year and 3-year (recent) history. Note that the 1D_5D correlation refers to the relationship between 1D post-earnings returns and following 5D returns. WYNN Correlation Between 1D, 5D, and 21D Historical Returns Occasionally, the performance of peers can impact post-earnings stock reactions. Indeed, the pricing-in may commence prior to the earnings announcement. Here is some historical information on Wynn Resorts stock's post-earnings performance compared to those of peers that reported earnings just before Wynn Resorts. For a fair comparison, peer stock returns also reflect post-earnings one-day (1D) returns. WYNN Correlation with Peer Earnings Discover more about the Trefis RV strategy, which has outperformed its all-cap stocks benchmark (combination of all three, the S&P 500, S&P mid-cap, and Russell 2000), generating strong returns for investors.
Yahoo
02-05-2025
- Business
- Yahoo
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two fixed-dose, dual-combination therapies of budesonid (an ICS) and formoterol fumarate (LABA) and Symbicort pressurized metered-dose inhaler (pMDI). KALOS and LOGOS included approximately 4,400 randomized trials met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines. No new safety or tolerability signals were identified for Breztri in KALOS or LOGOS. Full results from the two Phase 3 trials will be shared with regulatory authorities and presented at an upcoming medical meeting. Breztri is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan. In addition to the two registrational trials (KALOS and LOGOS), two qualifying trials, LITHOS and VATHOS, also met their primary endpoints. LITHOS and VATHOS included approximately 1,000 randomized patients. In April, Sanofi SA (NASDAQ:SNY) reported preliminary results from the TIDE-Asthma phase 2 study of amlitelimab and its efficacy in heterogeneous inflammatory asthma. The primary endpoint of the annualized exacerbation rate at week 48 was not met at the highest dose level, leading to nominal significance at the medium and low doses. Treatment with amlitelimab led to nominally significant and clinically meaningful reductions in asthma exacerbations at the medium dose tested and a numerically greater reduction in exacerbations at the high dose at week 60. A nominally significant and clinically meaningful improvement in secondary endpoints of lung function and asthma control was evident. In a patient subgroup, amlitelimab showed nominally significant and clinically meaningful improvements in exacerbations (with a reduction of more than 70%), lung function, and asthma control at week 60. AstraZeneca announced in its first-quarter presentation (PDF) on Tuesday that it had stopped working on a phase 1 Alzheimer's disease drug and two phase 2 programs for migraine and osteoarthritis pain and painful diabetic neuropathy. On Tuesday, the European pharma giant reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the consensus of $13.71 billion, driven by double-digit growth in oncology and biopharmaceuticals. Price Action: AZN stock is up 1.52% at $71.58 at the last check Friday. Read Next:Photo by Piotr Swat Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ASTRAZENECA (AZN): Free Stock Analysis Report This article AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
